2023 年医药板块业绩总体平稳，2024Q1 呈现恢复性增长。医药板块所有上市公司（剔除同口径非经常损益、商誉、价值变动净收益变动较大的公司以及新股，同时剔除部分经营存在异常波动的公司，剔除新冠业务基数较大公司，详见图 1、2 备注）2023 年营业收入同比增长 6.71%，归属上市公司股东的净利润同比增长 1.69%，扣非归母净利润同比增长 4.17%。2024 一季度年营业收入同比增长 1.32%，归属上市公司股东的净利润同比下降 0.17%，扣非归母净利润同比增长 2.28%。2024 年一季度医药板块扣非归母净利润稳健增长，多数公司业绩符合预期，体现出医药板块业绩具备较强韧性。

百年诺华，走向专注。诺华及其前身可追溯到250多年前。自公司成立以来，诺华制药经历过数次经营架构的调整。在2015年剥离疫苗业务，2018年剥离消费保健业务，2019年完成眼科业务的分拆，2023年完成对仿制药公司Sandoz的剥离后，诺华目前专注于创新药板块。诺华当下主要经营的四大板块包括①心血管、肾脏和代谢,②免疫,③神经科学,④肿瘤,2023年营业收入中肿瘤板块的占比最高，达到42.71%，其次为免疫学板块，占比24.51%，心血管、肾脏和代谢板块占比20.08%，神经科学板块占比12.71%。

The Global bariatric surgeries market is estimated to grow at a CAGR of 15.9% from 2022 to 2030. Key factors driving the market growth are the increasing prevalence of obesity and growing demand for minimally invasive surgeries are driving the market growth. However, the stringent regulatory policies and increase in safety concerns restrain the market growth.

The automated external defibrillators market is estimated to grow at a CAGR of 4.5% from 2020 to 2030. Key factors driving the market growth are increasing prevalence of cardiovascular diseases and rising training and awareness programs on automated external defibrillators. Whereas performance issues related to automated external defibrillators is hindering the market growth.

The global aesthetic lasers market is estimated to grow at a CAGR of 12.3% from 2022 to 2030. Key factors driving the market growth are growing adoption of non-invasive aesthetic procedures and increasing prevalence of skin disorders along with growing awareness about beauty devices. However, risks and complications associated with procedures and stringent safety regulations hinders the market growth.

Bisulfite conversion has emerged as a key trend in the global DNA methylation detection technology market, maintaining its position as the gold standard. Its continued prominence can be attributed to its unmatched accuracy and reliability in deciphering DNA methylation patterns, which are crucial for understanding the epigenetic regulation of genes in health and disease. Despite the development of alternative technologies, bisulfite conversion remains indispensable in both research and clinical settings, ensuring that DNA methylation analysis maintains the highest standards of precision.

The healthcare landscape has undergone a remarkable transformation with the emergence of digital biomarkers. Digital biomarkers represent a pivotal shift in how healthcare professionals collect, analyze, and act upon patient data, fundamentally altering how diseases are diagnosed, treated, and monitored.

The global endoscopy procedures market is estimated to grow at a CAGR of 7.0% from 2022 to 2030. Key factors driving the market growth are growing preference for minimally invasive surgeries and increasing prevalence of cancer are the key factors driving the market. However, the risks of infections associated with endoscopic procedures hamper the market growth.

The global cerebrospinal fluid management market is estimated to grow at a CAGR of 5.3% from 2022 to 2030. Key factors driving the market growth are increasing incidences of CSF leak and growing developments for CSF management products. However, the risk associated with CSF shunts hinders the market growth.